101 related articles for article (PubMed ID: 15608424)
1. p53-based immunotherapy of cancer. Approaches ro reversing unresponsiveness to T lymphocytes and preventing tumor escape.
De Leo AB
Adv Otorhinolaryngol; 2005; 62():134-50. PubMed ID: 15608424
[TBL] [Abstract][Full Text] [Related]
2. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
3. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
4. Development of vaccines against self-antigens: the p53 paradigm.
Chada S; Mhashilkar A; Roth JA; Gabrilovich D
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
[TBL] [Abstract][Full Text] [Related]
5. Impact of p53-based immunization on primary chemically-induced tumors.
Cicinnati VR; Dworacki G; Albers A; Beckebaum S; Tüting T; Kaczmarek E; DeLeo AB
Int J Cancer; 2005 Mar; 113(6):961-70. PubMed ID: 15514940
[TBL] [Abstract][Full Text] [Related]
6. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M
Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377
[TBL] [Abstract][Full Text] [Related]
7. Wildtype p53-specific antibody and T-cell responses in cancer patients.
Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
9. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
Song GY; Gibson G; Haq W; Huang EC; Srivasta T; Hollstein M; Daftarian P; Wang Z; Diamond D; Ellenhorn JD
Cancer Immunol Immunother; 2007 Aug; 56(8):1193-205. PubMed ID: 17219151
[TBL] [Abstract][Full Text] [Related]
10. p53 as a target for anti-cancer immunotherapy.
Chen HL; Carbone DP
Mol Med Today; 1997 Apr; 3(4):160-7. PubMed ID: 9134529
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
12. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
13. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor.
Abastado JP
Cancer Res; 2012 May; 72(9):2159-61. PubMed ID: 22549945
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
Bertholet S; Iggo R; Corradin G
Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
[TBL] [Abstract][Full Text] [Related]
15. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
16. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
17. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
18. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
[TBL] [Abstract][Full Text] [Related]
20. Anti-p53-directed immunotherapy of malignant disease.
Theobald M; Offringa R
Expert Rev Mol Med; 2003 Mar; 5(11):1-13. PubMed ID: 14987396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
